Susceptibility Test Powders, Antimycobacterial

What the Data Shows About Susceptibility Test Powders, Antimycobacterial

The FDA MAUDE database aggregates 756 adverse-event reports for Susceptibility Test Powders, Antimycobacterial spanning the period from 2021 through 2026. Of these, 0 are classified as death reports, 4 as injury reports, and 752 as malfunction reports under FDA adverse-event categorization rules. Report counts do not by themselves indicate a device is unsafe — widely used devices and longer market histories naturally generate larger raw counts, so proportional and comparative reads are more informative than totals alone.

The adverse-event profile breaks down across 2 distinct event types and 3 reported patient-outcome categories, giving a multi-dimensional view that goes beyond a single headline number. A total of 6 distinct product-problem codes appear in the reports, with Incorrect, Inadequate or Imprecise Result or Readings topping the list at 721 reports. Reports are associated with 8 different manufacturers in the MAUDE record, reflecting both OEMs and repackagers of this device category.

Annual reporting volume is tracked across 6 years of MAUDE data, with the peak single-year volume reaching 533 reports — trend shape often reflects changes in device adoption, reporting rules, or FDA enforcement focus rather than underlying device behavior alone. Events are documented across 2 reported care-setting categories (hospital, home, ambulatory surgery center, etc.). All figures reflect the openFDA MAUDE snapshot last refreshed on 2026-05-15. This page is informational and is not medical advice — discuss device-safety questions with your healthcare provider.